X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1368) 1368
Publication (152) 152
Newsletter (99) 99
Newspaper Article (63) 63
Book Review (13) 13
Transcript (11) 11
Conference Proceeding (9) 9
Book Chapter (3) 3
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bendamustine (1026) 1026
humans (865) 865
index medicus (725) 725
oncology (535) 535
hematology (529) 529
rituximab (481) 481
bendamustine hydrochloride (443) 443
male (431) 431
female (425) 425
aged (384) 384
middle aged (384) 384
antineoplastic combined chemotherapy protocols - therapeutic use (337) 337
chemotherapy (332) 332
lymphomas (294) 294
cancer (293) 293
treatment outcome (251) 251
adult (236) 236
care and treatment (236) 236
leukemia, lymphocytic, chronic, b-cell - drug therapy (204) 204
nitrogen mustard compounds - therapeutic use (196) 196
nitrogen mustard compounds - administration & dosage (194) 194
non-hodgkins-lymphoma (187) 187
aged, 80 and over (177) 177
therapy (174) 174
chronic lymphocytic leukemia (173) 173
antineoplastic agents - therapeutic use (170) 170
antineoplastic agents (159) 159
cyclophosphamide (154) 154
antimitotic agents (152) 152
bendamustine hydrochloride - administration & dosage (147) 147
chronic lymphocytic-leukemia (144) 144
multicenter (142) 142
antineoplastic combined chemotherapy protocols - adverse effects (141) 141
open-label (141) 141
nitrogen mustard compounds - adverse effects (136) 136
trial (134) 134
plus rituximab (132) 132
lymphoma (129) 129
research (129) 129
fludarabine (128) 128
leukemia (125) 125
pharmacology & pharmacy (124) 124
bortezomib (123) 123
multiple myeloma (122) 122
mantle cell lymphoma (119) 119
medicine & public health (119) 119
recurrence (117) 117
phase-ii (111) 111
disease-free survival (109) 109
drug therapy (109) 109
1st-line treatment (107) 107
transplantation (107) 107
patients (106) 106
antineoplastic agents, alkylating - therapeutic use (105) 105
prognosis (105) 105
survival (104) 104
follicular lymphoma (102) 102
bendamustine plus rituximab (100) 100
clinical trials (96) 96
rituximab - administration & dosage (96) 96
bendamustine hydrochloride - therapeutic use (95) 95
phase-ii trial (95) 95
analysis (94) 94
lymphoma, non-hodgkin - drug therapy (94) 94
antibodies, monoclonal, murine-derived - administration & dosage (92) 92
antineoplastic combined chemotherapy protocols - administration & dosage (91) 91
lenalidomide (90) 90
lymphoma, mantle-cell - drug therapy (89) 89
combination (88) 88
progression-free survival (86) 86
stem-cell transplantation (86) 86
non-hodgkin's lymphomas (84) 84
retrospective studies (83) 83
animals (80) 80
hematology, oncology and palliative medicine (78) 78
hemic and lymphatic diseases (77) 77
non-hodgkin lymphoma (76) 76
chlorambucil (74) 74
stem cells (74) 74
toxicity (74) 74
antineoplastic agents - administration & dosage (73) 73
antineoplastic agents - adverse effects (73) 73
efficacy (73) 73
previously untreated patients (73) 73
remission induction (73) 73
indolent (72) 72
multiple myeloma - drug therapy (72) 72
cll (70) 70
apoptosis (69) 69
drug administration schedule (69) 69
b-cell (67) 67
bendamustine hydrochloride - adverse effects (67) 67
neoplasm staging (67) 67
relapse (67) 67
internal medicine (65) 65
salvage therapy (65) 65
non-hodgkin-lymphoma (64) 64
immunotherapy (62) 62
ibrutinib (61) 61
diagnosis (60) 60
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1448) 1448
German (38) 38
Japanese (19) 19
Russian (13) 13
Polish (10) 10
French (8) 8
Spanish (5) 5
Chinese (2) 2
Czech (2) 2
Hungarian (2) 2
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5626 - 5626
Abstract Introduction Bendamustine (B) and Melflufen (Mel) are Non-Food and Drug Administration (FDA) approved novel alkylators that exert their cytotoxic... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 4472 - 4472
Abstract Background: In patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL), novel therapies are needed to prolong disease control.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5847 - 5847
Abstract Background and Aim: The incidence and outcomes of patients with cancer diagnoses are reported annually as SEERs in few but not all countries. Clinical... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 4781 - 4781
Abstract Background: Recent introductions of multiple myeloma (MM) chemotherapy agents have improved response and survival rates, yet substantial unmet... 
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, p. 225
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1932 - 1938
Abstract Background Venetoclax is a selective, potent inhibitor of the anti-apoptotic B-cell leukemia/lymphoma-2 protein approved for treatment of chronic... 
relapsed/refractory NHL | phase Ib | venetoclax | bendamustine-rituximab | relapsed | refractory NHL | Original | bendamustine–rituximab
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 10/2016, Volume 146, pp. 852 - 860
Journal Article
Hematological Oncology, ISSN 0278-0232, 06/2019, Volume 37, Issue S2, p. 86
Journal Article
Lancet Haematology, The, ISSN 2352-3026, 2016, Volume 4, Issue 1, pp. e15 - e23
Journal Article
Apoptosis, ISSN 1360-8185, 06/2017, Volume 22, Issue 6, pp. 827 - 840
Histone deacetylase inhibitors (HDACis) have emerged as a new class of anticancer agents, targeting the biological process including cell cycle and apoptosis.... 
Bendamustine | Synergistic effect | Lymphoma | Ricolinostat | Apoptosis | MULTIPLE-MYELOMA | MULTICENTER | AGGRESOME FORMATION | ACY-1215 | ACETYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | MECHANISMS | CELL BIOLOGY | THIOREDOXIN | IN-VIVO | LENALIDOMIDE | HISTONE DEACETYLASE INHIBITORS | Bendamustine Hydrochloride - therapeutic use | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Lymphoma, Non-Hodgkin - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Histone Deacetylase 6 - metabolism | Lymphoma - drug therapy | Mesenchymal Stromal Cells - cytology | Microtubules - metabolism | Tubulin - metabolism | Caspases - metabolism | Microtubules - drug effects | Interleukin-10 - metabolism | Lymphoma - pathology | Clone Cells | Proto-Oncogene Proteins c-akt - metabolism | Hydroxamic Acids - pharmacology | Lymphoma, Non-Hodgkin - drug therapy | Cell Survival - drug effects | Mesenchymal Stromal Cells - drug effects | Endoplasmic Reticulum Stress - drug effects | Histone Deacetylase 6 - antagonists & inhibitors | Cell Cycle Proteins - metabolism | Pyrimidines - pharmacology | Enzyme Activation - drug effects | Drug Synergism | Acetylation - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Bendamustine Hydrochloride - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Cell Proliferation - drug effects | Histone Deacetylase Inhibitors - therapeutic use | Proto-Oncogene Proteins c-bcl-2 | Cell Cycle - drug effects
Journal Article
R & D Focus Drug News, ISSN 1350-1135, 07/2019
Journal Article